{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:47:48Z","timestamp":1790200068059,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001203","name":"GlaxoSmithKline Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001203","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Travel Medicine and Infectious Disease"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.tmaid.2020.101908","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T16:43:24Z","timestamp":1605890604000},"page":"101908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Efficacy and safety of tafenoquine for malaria chemoprophylaxis (1998\u20132020): A systematic review and meta-analysis"],"prefix":"10.1016","volume":"39","author":[{"given":"Julian D.","family":"Maier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Siegfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nejla","family":"G\u00fcltekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeno","family":"Stanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Kevin","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-1099","authenticated-orcid":false,"given":"Martin P.","family":"Grobusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1075-7010","authenticated-orcid":false,"given":"Patricia","family":"Schlagenhauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmaid.2020.101908_bib1","series-title":"World malaria report 2019","author":"WHO","year":"2019"},{"key":"10.1016\/j.tmaid.2020.101908_bib2","author":"World Health Organization"},{"key":"10.1016\/j.tmaid.2020.101908_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2019.07.001","article-title":"Pre-travel malaria enquiries to the United Kingdom national travel advice line 2016: advice mainly needed on malaria maps and risk groups","author":"Kay","year":"2019","journal-title":"Trav Med Infect Dis"},{"key":"10.1016\/j.tmaid.2020.101908_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2017.12.005","article-title":"Abbreviated atovaquone-proguanil prophylaxis regimens in travellers after leaving malaria-endemic areas: a systematic review","author":"Savelkoel","year":"2018","journal-title":"Trav Med Infect Dis"},{"key":"10.1016\/j.tmaid.2020.101908_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2019.01.008","article-title":"The safety of atovaquone-proguanil for the prevention and treatment of malaria in pregnancy: a systematic review","author":"Andrejko","year":"2019","journal-title":"Trav Med Infect Dis"},{"key":"10.1016\/j.tmaid.2020.101908_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa021592","article-title":"Delayed onset of malaria - implications for chemoprophylaxis in travelers","volume":"349","author":"Schwartz","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmaid.2020.101908_bib7","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s40265-018-0979-2","article-title":"Tafenoquine: first Global approval","volume":"78","author":"Frampton","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.tmaid.2020.101908_bib8","series-title":"KODATEF\u00ae (tafenoquine) approved in Australia; first malaria prevention drug in more than two decades","author":"60\u00b0 Sixty Degrees Pharma","year":"2018"},{"key":"10.1016\/j.tmaid.2020.101908_bib9","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-018-2555-3","article-title":"Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines","author":"Berman","year":"2018","journal-title":"Malar J"},{"key":"10.1016\/j.tmaid.2020.101908_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00011-19","article-title":"8-aminoquinoline therapy for latent malaria","author":"Baird","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.tmaid.2020.101908_bib11","unstructured":"Grayson ML. Kucers' the use of antibiotics\u00a0: a clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs. n.d."},{"key":"10.1016\/j.tmaid.2020.101908_bib12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrd.2018.156","article-title":"Malaria medicine box expands","volume":"17","author":"Mullard","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.tmaid.2020.101908_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2017.04.005","article-title":"Prophylactic efficacy of primaquine for preventing Plasmodium falciparum and Plasmodium vivax parasitaemia in travelers: a meta-analysis and systematic review","volume":"17","author":"Kolifarhood","year":"2017","journal-title":"Trav Med Infect Dis"},{"key":"10.1016\/j.tmaid.2020.101908_bib14","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1128\/AAC.01183-06","article-title":"Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects","volume":"51","author":"Charles","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tmaid.2020.101908_bib15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1046\/j.0306-5251.2001.01482.x","article-title":"Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers","volume":"52","author":"Edstein","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.tmaid.2020.101908_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00711-18","article-title":"Population pharmacokinetics of tafenoquine, a novel antimalarial","volume":"62","author":"Thakkar","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tmaid.2020.101908_bib17","author":"GlaxoSmithKline"},{"key":"10.1016\/j.tmaid.2020.101908_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tay140","article-title":"Tafenoquine: integrating a new drug for malaria prophylaxis into travel medicine practice","volume":"26","author":"Freedman","year":"2019","journal-title":"J Trav Med"},{"key":"10.1016\/j.tmaid.2020.101908_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2017.05.008","article-title":"Tafenoquine for malaria prophylaxis in adults: an integrated safety analysis","author":"Novitt-Moreno","year":"2017","journal-title":"Trav Med Infect Dis"},{"key":"10.1016\/j.tmaid.2020.101908_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/trstmh\/trz052","article-title":"Tafenoquine for primary and terminal prophylaxis of malaria in apparently healthy people: a systematic review","author":"Rodrigo","year":"2019","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.tmaid.2020.101908_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.tmaid.2020.101908_bib22","article-title":"Tafenoquine for malaria chemoprophylaxis: a systematic review","author":"Maier","year":"2020","journal-title":"PROSPERO"},{"key":"10.1016\/j.tmaid.2020.101908_bib23","author":"The EndNote Team","year":"2013","journal-title":"EndNote"},{"key":"10.1016\/j.tmaid.2020.101908_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-016-0368-4","article-title":"Data extraction for complex meta-analysis (DECiMAL) guide","volume":"5","author":"Pedder","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.tmaid.2020.101908_bib25","unstructured":"R Core Team R: A language and environment for statistical computing 2020."},{"key":"10.1016\/j.tmaid.2020.101908_bib26","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"The BMJ"},{"key":"10.1016\/j.tmaid.2020.101908_bib27","author":"McCarthy"},{"key":"10.1016\/j.tmaid.2020.101908_bib28","doi-asserted-by":"crossref","DOI":"10.4269\/ajtmh.2009.81.356","article-title":"A randomized, double-blind, safety and tolerability study to assess the ophthalmic and renal effects of tafenoquine 200 mg weekly versus placebo for 6 months in healthy volunteers","author":"Leary","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.tmaid.2020.101908_bib29","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/cid\/ciy939","article-title":"Blood schizonticidal activity and safety of tafenoquine when administered as chemoprophylaxis to healthy, nonimmune participants followed by blood stage plasmodium falciparum challenge: a randomized, double-blind, placebo-controlled phase 1b study","volume":"69","author":"McCarthy","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tmaid.2020.101908_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(00)02352-7","article-title":"Malaria chemoprophylaxis with tafenoquine: a randomised study","author":"Lell","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.tmaid.2020.101908_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.42.5.1293","article-title":"Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial","author":"Brueckner","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tmaid.2020.101908_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00354-09","article-title":"Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects","author":"Nasveld","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tmaid.2020.101908_bib33","doi-asserted-by":"crossref","DOI":"10.1086\/367542","article-title":"A randomized, double\u2010blind, placebo\u2010controlled, dose\u2010ranging trial of tafenoquine for weekly prophylaxis against plasmodium falciparum","author":"Hale","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tmaid.2020.101908_bib34","author":"Jose Stoute"},{"key":"10.1016\/j.tmaid.2020.101908_bib35","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-13-49","article-title":"A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area","author":"Dow","year":"2014","journal-title":"Malar J"},{"key":"10.1016\/j.tmaid.2020.101908_bib36","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-015-0991-x","article-title":"Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries","author":"Dow","year":"2015","journal-title":"Malar J"},{"key":"10.1016\/j.tmaid.2020.101908_bib37","doi-asserted-by":"crossref","DOI":"10.1086\/424468","article-title":"Efficacy of monthly tafenoquine for prophylaxis of plasmodium vivax and multidrug\u2010resistant P. Falciparum malaria","author":"Walsh","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tmaid.2020.101908_bib38","doi-asserted-by":"crossref","DOI":"10.1086\/324081","article-title":"A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against plasmodium falciparum malaria","author":"Shanks","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tmaid.2020.101908_bib39","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40264-019-00839-w","article-title":"Randomized placebo-controlled trial evaluating the ophthalmic safety of single-dose tafenoquine in healthy volunteers","volume":"42","author":"Ackert","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.tmaid.2020.101908_bib40","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s10792-018-1003-2","article-title":"Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine\/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure","volume":"39","author":"Warrasak","year":"2019","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.tmaid.2020.101908_bib41","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1802537","article-title":"Tafenoquine versus primaquine to prevent relapse of plasmodium vivax malaria","author":"Llanos-Cuentas","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmaid.2020.101908_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(13)62568-4","article-title":"Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study","author":"Llanos-Cuentas","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.tmaid.2020.101908_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-9149(99)00700-6","article-title":"Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations","author":"Pollak","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.tmaid.2020.101908_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.survophthal.2016.11.008","article-title":"Drug-induced corneal epithelial changes","author":"Raizman","year":"2017","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.tmaid.2020.101908_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.24.5.615","article-title":"Relationships between chemical structures of 8-aminoquinolines and their capacities for radical cure of infections with Plasmodium cynomolgi in rhesus monkeys","author":"Schmidt","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tmaid.2020.101908_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2017.05.006","article-title":"Tafenoquine is not neurotoxic following supertherapeutic dosing in rats","author":"Dow","year":"2017","journal-title":"Trav Med Infect Dis"},{"key":"10.1016\/j.tmaid.2020.101908_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(07)70187-1","article-title":"Cardiotoxicity of antimalarial drugs","author":"White","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.tmaid.2020.101908_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.302","article-title":"Tafenoquine at therapeutic concentrations does not prolong fridericia-corrected QT interval in healthy subjects","author":"Green","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.tmaid.2020.101908_bib49","doi-asserted-by":"crossref","DOI":"10.4269\/ajtmh.16-0779","article-title":"Hemolytic potential of tafenoquine in female volunteers heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal volunteers","author":"Rueangweerayut","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.tmaid.2020.101908_bib50","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.23061.020","article-title":"Modelling primaquine-induced haemolysis in G6PD deficiency","author":"Watson","year":"2017","journal-title":"ELife"},{"key":"10.1016\/j.tmaid.2020.101908_bib51","doi-asserted-by":"crossref","DOI":"10.1046\/j.1365-3156.2002.00951.x","article-title":"Renal dysfunction in falciparum - malaria is detected more often when assessed by serum concentration of cystatin C instead of creatinine","author":"G\u00fcnther","year":"2002","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.tmaid.2020.101908_bib52","doi-asserted-by":"crossref","DOI":"10.1023\/A:1015842316177","article-title":"Simultaneous modeling of the pharmacokinetics and methemoglobin pharmacodynamics of an 8-aminoquinoline candidate antimalarial (WR 238605)","author":"Brueckner","year":"1991","journal-title":"Pharmaceut Res: An Official Journal of the American Association of Pharmaceutical Scientists"},{"key":"10.1016\/j.tmaid.2020.101908_bib53","doi-asserted-by":"crossref","DOI":"10.1093\/toxsci\/10.2.270","article-title":"Methemoglobin formation resulting from administration of candidate 8-aminoquinoline antiparasitic drugs in the dog","author":"Anders","year":"1988","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.tmaid.2020.101908_bib54","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-12-443","article-title":"Gender-specific distribution of mefloquine in the blood following the administration of therapeutic doses","volume":"12","author":"Wernsdorfer","year":"2013","journal-title":"Malar J"},{"key":"10.1016\/j.tmaid.2020.101908_bib55","doi-asserted-by":"crossref","DOI":"10.1111\/j.1708-8305.1996.tb00695.x","article-title":"User acceptability patterns for mefloquine and doxycycline malaria chemoprophylaxis","author":"Phillips","year":"1996","journal-title":"J Trav Med"},{"key":"10.1016\/j.tmaid.2020.101908_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.trstmh.2006.04.003","article-title":"Gender differences in gastrointestinal disturbances and plasma concentrations of tafenoquine in healthy volunteers after tafenoquine administration for post-exposure vivax malaria prophylaxis","author":"Edstein","year":"2007","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.tmaid.2020.101908_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/pds.2208","article-title":"Pitfalls in meta-analyses on adverse events reported from clinical trials","author":"Huang","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.tmaid.2020.101908_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.327.7423.1078","article-title":"Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study","author":"Schlagenhauf","year":"2003","journal-title":"Br Med J"}],"container-title":["Travel Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147789392030404X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147789392030404X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:06:04Z","timestamp":1761487564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147789392030404X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":58,"alternative-id":["S147789392030404X"],"URL":"https:\/\/doi.org\/10.1016\/j.tmaid.2020.101908","relation":{},"ISSN":["1477-8939"],"issn-type":[{"value":"1477-8939","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of tafenoquine for malaria chemoprophylaxis (1998\u20132020): A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Travel Medicine and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmaid.2020.101908","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101908"}}